PTGX
$95.24
Revenue | $4.71Mn |
Net Profits | $-39.34Mn |
Net Profit Margins | -834.87% |
Protagonist Therapeutics Inc’s revenue jumped 0.79% since last year same period to $4.71Mn in the Q3 2025. On a quarterly growth basis, Protagonist Therapeutics Inc has generated -15.04% fall in its revenue since last 3-months.
Protagonist Therapeutics Inc’s net profit fell -18.46% since last year same period to $-39.34Mn in the Q3 2025. On a quarterly growth basis, Protagonist Therapeutics Inc has generated -13.14% fall in its net profits since last 3-months.
Protagonist Therapeutics Inc’s net profit margin fell -17.53% since last year same period to -834.87% in the Q3 2025. On a quarterly growth basis, Protagonist Therapeutics Inc has generated -33.16% fall in its net profit margins since last 3-months.
EPS Estimate Current Quarter | -0.61 |
EPS Estimate Current Year | -0.61 |
Protagonist Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.61 - a -5.84% fall from last quarter’s estimates.
Protagonist Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.61.
Earning Per Share (EPS) | 0 |
Protagonist Therapeutics Inc’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Protagonist Therapeutics Inc has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2025-11-06 | -0.61 | 0 | 100% |
2025-08-06 | -0.58 | -0.55 | 5.17% |
2025-05-06 | 0.11 | -0.19 | -272.73% |